^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PM8001

    i
    Other names: PM8001, PM 8001
    Associations

    News

    Trials
    Company:
    Biotheus
    Drug class:
    PD-L1 inhibitor, TGFβ inhibitor
    Related drugs:
    Associations

    News

    Trials
    2years
    Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF‑β, in patients with advanced tumors. (ASCO 2022)
    PM8001 showed an acceptable safety profile and promising anti-tumor activity in advanced solid tumors, especially in patients previously treated with checkpoint inhibitors, which supports further studies to explore the safety and efficacy of PM8001 as a monotherapy and in combination with other anti-tumor agents. Global Phase II monotherapy and combination studies are currently ongoing.
    Clinical • P1/2 data
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    PM8001